An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic

Background: There are limited clinical data comparing extended dosing (ED) versus standard dosing (SD) of pembrolizumab for metastatic non-small-cell lung cancer. Methods: This retrospective study included patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥50% trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Moffat, Gordon Taylor, Hanna, Lilian, Hopman, Wilma, Fung, Andrea S, Gaudreau, Pierre-Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340130/
https://www.ncbi.nlm.nih.gov/pubmed/37431608
http://dx.doi.org/10.2217/imt-2022-0257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340130/
https://www.ncbi.nlm.nih.gov/pubmed/37431608
http://dx.doi.org/10.2217/imt-2022-0257

Ejemplares similares